Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in advanced or relapsed MALT lymphoma
NCT00373646Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jun 2006
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thalidomide in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, sponsored by Medical University of Vienna. Primary endpoint: Objective Response Rate at 6 months. Started Jun 2006; status: completed.
02
Drugs
thalidomide
03
Conditions
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT00373646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373646.